About efmoroctocog alfa
Recombinant factor VIII clotting factor
Used for
- Prevention and treatment of bleeding in haemophilia A.
- Control of bleeding during and after surgery in haemophilia A.
Usual adult dose
Intravenous dosing is individualised by weight, bleeding severity, factor level, and response. Typical doses are 20–50 IU/kg every 2–3 days for prevention; bleeding doses vary.
Usual dose in children
Intravenous dosing is individualised by weight and clinical response. Typical prevention is 25–65 IU/kg twice weekly or every 3–5 days; bleeding doses vary.
Common side effects
- Headache
- Joint pain
- Rash
- Injection-site reactions
Important warnings
- Allergic reactions, including severe reactions, can occur.
- Factor VIII inhibitors may develop and reduce treatment effectiveness.
- Seek prompt assessment for new bleeding or signs of an allergic reaction.
- Use only by intravenous injection as prescribed.
Pregnancy
Limited human data; use during pregnancy only when clearly needed and under specialist supervision.
Breastfeeding
Unknown whether it passes into breast milk; use only when clinically needed after weighing benefits and risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.